User profiles for Daniel Jenkin

Daniel Jenkin

Clinical Research Fellow, Jenner Institute, University of Oxford
Verified email at ndm.ox.ac.uk
Cited by 14403

[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …

…, D Gbesemete, C Green, B Hallis, MM Hou, D Jenkin… - The Lancet, 2020 - thelancet.com
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses

…, N Omo-Dare, D Koeckerling, A Flaxman, D Jenkin… - Cell, 2022 - cell.com
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …

[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …

…, I Hirsch, SHC Hodgson, A Izu, S Jackson, D Jenkin… - The Lancet, 2021 - thelancet.com
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …

…, M Greenland, C Hill, HC Hill, I Hirsch, A Izu, D Jenkin… - The Lancet, 2021 - thelancet.com
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

[HTML][HTML] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled …

…, A Finn, AL Flaxman, B Hallis, P Heath, D Jenkin… - The Lancet, 2020 - thelancet.com
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …

…, B Hallis, PT Heath, J Hay, HC Hill, D Jenkin… - The Lancet, 2021 - thelancet.com
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …

[HTML][HTML] T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

…, PM Folegatti, M Fuskova, CM Green, D Jenkin… - Nature medicine, 2021 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …

[HTML][HTML] Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

…, C Gilbride, R Halkerston, J Hill, D Jenkin… - Nature medicine, 2021 - nature.com
More than 190 vaccines are currently in development to prevent infection by the novel severe
acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing …

[HTML][HTML] Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials …

A Flaxman, NG Marchevsky, D Jenkin, J Aboagye… - The Lancet, 2021 - thelancet.com
Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …

[HTML][HTML] Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical …

…, J Fowler, C Gibbs, AL Goodman, D Jenkin… - The lancet HIV, 2021 - thelancet.com
Background Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40
million people globally living with HIV who might have less functional immunity and more …